The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Open accessAbstract
The cyclin-dependent kinases 4 and 6 (Cdk4/6) that drive progression through the G 1 phase of the cell cycle play a central role in the control of cell proliferation, and CDK deregulation is a frequent event in cancer. Cdk4/6 are regulated by the D-type cyclins, which bind to CDKs and activate the kinase, and by the INK4 family of inhibitors. INK4 proteins can bind both monomeric CDK, preventing its association with a cyclin, and also the CDK-cyclin complex, forming an inactive ternary complex. In vivo, binary INK4–Cdk4/6 complexes are more abundant than ternary INK4–Cdk4/6–cyclinD complexes, and it has been suggested that INK4 binding may lead to the eventual dissociation of the cyclin. Here we present the 2.9-Å crystal structure of the inactive ternary complex between Cdk6, the INK4 inhibitor p18 INK4c, and a D-type viral cyclin. The structure reveals that p18 INK4c inhibits the CDK–cyclin complex by distorting the ATP binding site and misaligning catalytic residues. p18 INK4c also distorts the cyclin-binding site, with the cyclin remaining bound at an interface that is substantially reduced in size. These observations support the model that INK4 binding weakens the cyclin's affinity for the CDK. This structure also provides insights into the specificity of the D-type cyclins for Cdk4/6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“INK4 inhibitors can bind both monomeric Cdk4/6 (Serrano et al. 1993; Hall et al. 1995; Parry et al. 1995) and cyclinD-bound Cdk4/6 (Hirai et al. 1995; Adachi et al. 1997; Reynisdottir and Massague 1997) and appear to use multiple mechanisms to inhibit the CDK and halt the progression of the cell…”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“…(for review, see Hall and Peters 1996): An INK4 inhibitor, p16INK4a (p16), is a tumor suppressor that is altered in >50% of certain tumor types (Kamb et al. 1994; Nobori et al. 1994; Hall and Peters 1996); cyclinD is often amplified in breast and prostate cancer (Hall and Peters 1996);…”
BackgroundThe relation between the divergence of sequence and structure in proteins.
Chothia, C., & Lesk, A. M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04288.x · Cited by 2,458 · cited 1×
“The first cyclin repeat of K-cyclin is more similar to that of cyclinA (RMS deviation of 0.71 Å for all 96 C atoms) than would be expected based on the 28% sequence identity (Chothia and Lesk 1986), underlining the critical role of this domain in CDK binding.”
BackgroundInfluentialDeletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“…types (Kamb et al. 1994; Nobori et al. 1994; Hall and Peters 1996); cyclinD is often amplified in breast and prostate cancer (Hall and Peters 1996); mutations in Cdk4 that render it refractory to inhibition by INK4 have been identified in several cancer cases (Wolfel et al. 1995; Zuo et al. 1996).”
BackgroundGenetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483 · cited 1×
“GENES & DEVELOPMENT 14:3115–3125 © 2000 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/00 $5.00; www.genesdev.org 3115 the assembly of the Cdk4/6–cyclinD complex (Stepanova et al. 1996) and the ability of INK4s to compete with Cdc37 binding to Cdk4/6 (Lamphere et al. 1997; Russo et al. 1998).”
BackgroundInfluentialMcConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1981 · Cited by 238 · cited 2×
“The relative contribution of these two INK4 activities to cell cycle arrest has been a point of debate, as several studies have shown that the majority of p16 is found in binary complexes with Cdk4/6 in vivo (Parry et al. 1995; McConnell et al. 1999).”
Background
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
High-affinity binders selected from designed ankyrin repeat protein libraries
Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G., & Plückthun, A. (2004) · Nature Biotechnology · doi:10.1038/nbt962 · Cited by 656
“However, the interaction with CDK4/6 leads to structural alterations in the targe”
BackgroundAnkyrin Repeat: A Unique Motif Mediating Protein−Protein Interactions
Li, J., Mahajan, A., & Tsai, M.-D. (2006) · Biochemistry · doi:10.1021/bi062188q · Cited by 651
Proliferative capacity of the corneal endothelium
Joyce, N. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00065-4 · Cited by 611
MADDIKA, S., ANDE, S., PANIGRAHI, S., PARANJOTHY, T., WEGLARCZYK, K., ZUSE, A., ESHRAGHI, M., MANDA, K., WIECHEC, E., & LOS, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.003 · Cited by 461
Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W., & Pavletich, N. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.022 · Cited by 460
Self-citationStructure-Based Assembly of Protein Complexes in Yeast
Aloy, P., Böttcher, B., Ceulemans, H., Leutwein, C., Mellwig, C., Fischer, S., Gavin, A.-C., Bork, P., Superti-Furga, G., Serrano, L., et al. (2004) · Science · doi:10.1126/science.1092645 · Cited by 383
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Edgetic perturbation models of human inherited disorders
Zhong, Q., Simonis, N., Li, Q., Charloteaux, B., Heuze, F., Klitgord, N., Tam, S., Yu, H., Venkatesan, K., Mou, D., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.80 · Cited by 359
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
Agarwal, S. K., Mateo, C. M., & Marx, S. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2083 · Cited by 318
Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., & Xiong, Y. (2007) · Genes & Development · doi:10.1101/gad.1499407 · Cited by 311
Binding of the 7SK snRNA turns the HEXIM1 protein into a P‐TEFb (CDK9/cyclin T) inhibitor
Michels, A. A., Fraldi, A., Li, Q., Adamson, T. E., Bonnet, F., Nguyen, V. T., Sedore, S. C., Price, J. P., Price, D. H., Lania, L., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600275 · Cited by 303
Structural Basis of the Cks1-Dependent Recognition of p27Kip1 by the SCFSkp2 Ubiquitin Ligase
Hao, B., Zheng, N., Schulman, B. A., Wu, G., Miller, J. J., Pagano, M., & Pavletich, N. P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.003 · Cited by 301
Self-citationSignaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Rubin, S. M., Gall, A.-L., Zheng, N., & Pavletich, N. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.044 · Cited by 257
Self-citationBaughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
“It can also form a ternary complex with Cdk4/6-cyclin D and inhibit Cdk4/6 (37).”
BackgroundTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor
Diribarne, G., & Bensaude, O. (2009) · RNA Biology · doi:10.4161/rna.6.2.8115 · Cited by 130
Computed cancer interactome explains the effects of somatic mutations in cancers
Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31
Metadata
- Authors
- Jeffrey, P. D., Tong, L., & Pavletich, N. P.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-12-15
- Volume
- 14
- Issue
- 24
- Pages
- 3115-3125
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2075731214
- Cited by
- 239
- References
- 11
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.